These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35800411)

  • 1. Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors.
    Singh AK; Singh R
    World J Diabetes; 2022 Jun; 13(6):466-470. PubMed ID: 35800411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
    Monda VM; Voci C; Strollo F; Passaro A; Greco S; Monesi M; Bigoni R; Porcellati F; Piani D; Satta E; Gentile S
    Diabetes Ther; 2023 Dec; 14(12):2127-2142. PubMed ID: 37801224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.
    Kutz A; Kim DH; Wexler DJ; Liu J; Schneeweiss S; Glynn RJ; Patorno E
    Diabetes Care; 2023 Nov; 46(11):2004-2014. PubMed ID: 37677118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.
    Kunutsor SK; Zaccardi F; Balasubramanian VG; Gillies CL; Aroda VR; Seidu S; Davies MJ; Khunti K
    Diabetes Obes Metab; 2024 May; 26(5):1837-1849. PubMed ID: 38379094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
    Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
    Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
    Pan X; Xu S; Li J; Tong N
    Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
    Kohsaka S; Takeda M; Kidani Y; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():28-39. PubMed ID: 33835640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.
    Colosimo S; Ravaioli F; Petroni ML; Brodosi L; Marchignoli F; Barbanti FA; Sasdelli AS; Marchesini G; Pironi L
    Liver Int; 2021 Apr; 41(4):731-742. PubMed ID: 33497019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
    Hu J; Chen L
    Prim Care Diabetes; 2021 Apr; 15(2):227-233. PubMed ID: 32888896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized.
    Wood SJ; Bell JS; Magliano DJ; Shaw JE; Cesari M; Ilomaki J
    Front Pharmacol; 2022; 13():886834. PubMed ID: 35903329
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis.
    Wang S; Wu T; Zuo Z; Jin P; Luo X; Deng M
    Eur J Prev Cardiol; 2022 Jan; 28(16):1840-1849. PubMed ID: 34136913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.
    Goldney J; Sargeant JA; Davies MJ
    Diabetologia; 2023 Oct; 66(10):1832-1845. PubMed ID: 37597048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.
    Dong M; Wen S; Zhou L
    Diabetes Metab Syndr Obes; 2022; 15():2583-2597. PubMed ID: 36035518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.